MedPath

Prevention of Paclitaxel Neuropathy With Cryotherapy

Phase 2
Conditions
Breast Cancer
Interventions
Other: Cryotherapy
Registration Number
NCT02230319
Lead Sponsor
Medical Oncology & Hematology Associates of Northern Virginia
Brief Summary

The purpose of this study is to determine if cryotherapy can effectively decrease the rate of neuropathy in patients undergoing weekly paclitaxel treatments.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
39
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
CryotherapyCryotherapyEach patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
CryotherapyPaclitaxelEach patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
Primary Outcome Measures
NameTimeMethod
Incidence of grade 2 peripheral neuropathies induced by weekly paclitaxel.From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.
Secondary Outcome Measures
NameTimeMethod
Rate of completion of weekly adjuvant paclitaxel with the use of cryotherapy.From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.

Trial Locations

Locations (1)

Medical Oncology & Hematology Associates of Northern Virginia

🇺🇸

Reston, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath